Cargando…
Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310101/ https://www.ncbi.nlm.nih.gov/pubmed/35899115 http://dx.doi.org/10.3389/fphar.2022.898680 |
_version_ | 1784753316363763712 |
---|---|
author | Ma, Xiao Xie, Shuying Wang, Ruilin Wang, Zhongxia Jing, Manyi Li, Haotian Wei, Shizhang Liu, Honghong Li, Jianyu He, Qingyong Zhao, Yanling |
author_facet | Ma, Xiao Xie, Shuying Wang, Ruilin Wang, Zhongxia Jing, Manyi Li, Haotian Wei, Shizhang Liu, Honghong Li, Jianyu He, Qingyong Zhao, Yanling |
author_sort | Ma, Xiao |
collection | PubMed |
description | Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect on CNG, a clinical trial was conducted. Metabolomics was used to explore its deep mechanism. Methods: A total of 14 patients with CNG were recruited from October 2020 to March 2021 (ChiCTR2000040549). The endoscopy and histopathological changes were evaluated as efficacy. Serum samples were prepared and detected by performing widely targeted metabolome using UPLC. Multivariate statistical analysis was conducted to identify potential differential metabolites and signaling pathways. Last, the signal-related inflammatory factors containing COX-2, IL-4, and IL-17 were confirmed via immunohistochemical staining and enzyme-linked immunosorbent assay. Results: ZJP was able to alleviate several indexes of mucosal injury under endoscopy and histology. Erosion and bile reflux, but not red plaques and hemorrhage, were downregulated by ZJP. In addition, it could remarkably alleviate active chronic inflammation. A total of 14 potential metabolites, namely, hypoxanthine, adipic acid, D-ribono-1,4-lactone, L-sepiapterin, imidazoleacetic acid, sebacate, ADP-ribose, 4-hydroxybenzyl alcohol, 11,12-EET, 15-OxoETE, 12-OxoETE, (±)8-HETE, glycyrrhizinate, and DL-aminopimelic acid, were discriminated by metabolomics. Moreover, certain amino acid metabolism got significance during the disease progress and treatment. The related inflammatory factors including COX-2, IL-4, and IL-17 were inhibited by ZJP in both mucosa and serum. Conclusion: All these results indicated that ZJP partially acts as an inflammatory suppressor to regulate comprehensive metabolism disorders. This might be an important mechanism of ZJP in the treatment of CNG. |
format | Online Article Text |
id | pubmed-9310101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93101012022-07-26 Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis Ma, Xiao Xie, Shuying Wang, Ruilin Wang, Zhongxia Jing, Manyi Li, Haotian Wei, Shizhang Liu, Honghong Li, Jianyu He, Qingyong Zhao, Yanling Front Pharmacol Pharmacology Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect on CNG, a clinical trial was conducted. Metabolomics was used to explore its deep mechanism. Methods: A total of 14 patients with CNG were recruited from October 2020 to March 2021 (ChiCTR2000040549). The endoscopy and histopathological changes were evaluated as efficacy. Serum samples were prepared and detected by performing widely targeted metabolome using UPLC. Multivariate statistical analysis was conducted to identify potential differential metabolites and signaling pathways. Last, the signal-related inflammatory factors containing COX-2, IL-4, and IL-17 were confirmed via immunohistochemical staining and enzyme-linked immunosorbent assay. Results: ZJP was able to alleviate several indexes of mucosal injury under endoscopy and histology. Erosion and bile reflux, but not red plaques and hemorrhage, were downregulated by ZJP. In addition, it could remarkably alleviate active chronic inflammation. A total of 14 potential metabolites, namely, hypoxanthine, adipic acid, D-ribono-1,4-lactone, L-sepiapterin, imidazoleacetic acid, sebacate, ADP-ribose, 4-hydroxybenzyl alcohol, 11,12-EET, 15-OxoETE, 12-OxoETE, (±)8-HETE, glycyrrhizinate, and DL-aminopimelic acid, were discriminated by metabolomics. Moreover, certain amino acid metabolism got significance during the disease progress and treatment. The related inflammatory factors including COX-2, IL-4, and IL-17 were inhibited by ZJP in both mucosa and serum. Conclusion: All these results indicated that ZJP partially acts as an inflammatory suppressor to regulate comprehensive metabolism disorders. This might be an important mechanism of ZJP in the treatment of CNG. Frontiers Media S.A. 2022-07-11 /pmc/articles/PMC9310101/ /pubmed/35899115 http://dx.doi.org/10.3389/fphar.2022.898680 Text en Copyright © 2022 Ma, Xie, Wang, Wang, Jing, Li, Wei, Liu, Li, He and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ma, Xiao Xie, Shuying Wang, Ruilin Wang, Zhongxia Jing, Manyi Li, Haotian Wei, Shizhang Liu, Honghong Li, Jianyu He, Qingyong Zhao, Yanling Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title | Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title_full | Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title_fullStr | Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title_full_unstemmed | Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title_short | Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis |
title_sort | metabolomics profiles associated with the treatment of zuojin pill on patients with chronic nonatrophic gastritis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310101/ https://www.ncbi.nlm.nih.gov/pubmed/35899115 http://dx.doi.org/10.3389/fphar.2022.898680 |
work_keys_str_mv | AT maxiao metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT xieshuying metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT wangruilin metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT wangzhongxia metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT jingmanyi metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT lihaotian metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT weishizhang metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT liuhonghong metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT lijianyu metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT heqingyong metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis AT zhaoyanling metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis |